A. Akwabi-Ameyaw et al. / Bioorg. Med. Chem. Lett. 18 (2008) 4339–4343
4343
22. Fiorucci, S.; Rizzo, G.; Antonelli, E.; Renga, B.; Mencarelli, A.; Riccardi, L.;
Morelli, A.; Pruzanski, M.; Pellicciari, R. J. Pharmacol. Exp. Ther. 2005, 315, 58.
23. Fiorucci, S.; Rizzo, G.; Antonelli, E.; Renga, B.; Mencarelli, A.; Riccardi, L.;
Orlandi, S.; Pruzanski, M.; Morelli, A.; Pellicciari, R. J. Pharmacol. Exp. Ther. 2005,
314, 584.
24. Kim, I.; Morimura, K.; Shah, Y.; Yang, Q.; Ward, J. M.; Gonzalez, F. J.
Carcinogenesis 2007, 28, 940.
25. Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore, D. D.; Huang, W. Cancer Res. 2007, 67,
863.
Supplementary data
Supplementary data associated with this article can be found, in
References
26. Hanniman, E. A.; Lambert, G.; McCarthy, T. C.; Sinal, C. J. J. Lipid Res. 2005, 46,
2595.
27. Zhang, Y.; Wang, X.; Vales, C.; Lee, F. Y.; Lee, H.; Lusis, A. J.; Edwards, P. A.
Arterioscler. Thromb., Vasc. Biol. 2006, 26, 2316.
1. Zhang, Y.; Edwards, P. A. FEBS Lett. 2008, 582, 10.
2. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.;
Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shanz, B. Science 1999, 284,
1362.
28. Moschetta, A.; Bookout, A. L.; Mangelsdorf, D. J. Nat. Med. 2004, 10, 1352.
29. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P.
R.; Morelli, A.; Parks, D. J.; Willson, T. M. J. Med. Chem. 2002, 45, 3569.
30. Downes, M.; Verdecia, M. A.; Roecker, A. J.; Hughes, R.; Hogenesch, J. B.; Kast-
Woelbern, H. R.; Bowman, M. E.; Ferrer, J.-L.; Anisfeld, A. M.; Edwards, P. A.;
Rosenfeld, J. M.; Alvarez, J. G. A.; Noel, J. P.; Nicolaou, K. C.; Evans, R. M. Mol. Cell
2003, 11, 1079.
31. Kuo, C. H.; Hook, J. B.; Bernstein, J. Toxicology 1981, 22, 149.
32. Sugihara, K.; Kitamura, S.; Sanoh, S.; Ohta, S.; Fujimoto, N.; Maruyama, S.; Ito,
A. Toxicol. Appl. Pharmacol. 2000, 167, 46.
33. Deaton, D. N.; McFadyen, R. B.; Navas, F., III; Caldwell, R.; Spearing, P. K. PCT Int.
Appl. WO 076260, 2007.; Deaton, D. N.; McFadyen, R. B.; Navas, F., III; Caldwell,
R.; Spearing, P. K. Chem. Abstr. 2007, 147, 143407.
34. Morand, E. F.; Iskander, M.N. PCT Int. Appl. WO 104178, 2003; Morand, E. F.;
Iskander, M. N. Chem. Abstr. 2003, 140, 27670.
3. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer,
S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M.
Science 1999, 284, 1365.
4. Forman, B. M.; Goode, E.; Chen, J.; Oro, A. E.; Bradley, D. J.; Perlmann, T.;
Noonan, D. J.; Burka, L. T.; McMorris, T.; Lamph, W. W.; Evans, R. M.;
Weinberger, C. Cell 1995, 81, 687.
5. Higashiyama, H.; Kinoshita, M.; Asano, S. Acta Histochem. 2008, 110, 86.
6. Sinal, C. J.; Tohkin, M.; Miyata, M.; Ward, J. M.; Lambert, G.; Gonzalez, F. J. Cell
2000, 102, 731.
7. Rizzo, G.; Renga, B.; Mencarelli, A.; Pellicciari, R.; Fiorucci, S. Curr. Drug Targets:
Immune, Endocr. Metab. Disord. 2005, 5, 289.
8. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, A. M.; Chandra, G.; Plunket, K.
D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. A.; Willson, T.
M. J. Med. Chem. 2000, 43, 2971.
9. Watanabe, M.; Houten, S. M.; Wang, L.; Moschetta, A.; Mangelsdorf, D. J.;
Heyman, R. A.; Moore, D. D.; Auwerx, J. J. Clin. Invest. 2004, 113, 1408.
10. Lambert, G.; Amar, M. J. A.; Guo, G.; Brewer, H. B., Jr.; Gonzalez, F. J.; Sinal, C. J. J.
Biol. Chem. 2003, 278, 2563.
35. Although methyl 7-hydroxy-2-naphthoate 3c is known in the literature, it was
prepared from commercially available 7-methoxy-2-naphthol in three
synthetic steps. First, 7-methoxy-2-naphthol was converted into the triflate
with trifluoromethanesulfonic anhydride. Then, palladium-mediated
11. Zhang, Y.; Lee, F. Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F. J.; Willson, T. M.;
Edwards, P. A. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 1006.
carbonylation of the triflate under
a carbon monoxide atmosphere in
methanol and N,N-dimethylformamide provided methyl 7-methoxy-2-
naphthoate. Finally, cleavage of the methyl ether with boron tribromide gave
the desired methyl 7-hydroxy-2-naphthoate 3c.
12. Ma, K.; Saha, P. K.; Chan, L.; Moore, D. D. J. Clin. Invest. 2006, 116, 1102.
13. Cariou, B.; van Harmelen, K.; Duran-Sandoval, D.; van Dijk, T.; Grefhorst, A.;
Bouchaert, E.; Fruchart, J.-C.; Gonzalez, F. J.; Kuipers, F.; Staels, B. FEBS Lett.
2005, 579, 4076.
14. Inagaki, T.; Choi, M.; Moschetta, A.; Peng, L.; Cummins, C. L.; McDonald, J. G.;
Luo, G.; Jones, S. A.; Goodwin, B.; Richardson, J. A.; Gerard, R. D.; Repa, J. J.;
Mangelsdorf, D. J.; Kliewer, S. A. Cell Metab. 2005, 2, 217.
15. Inagaki, T.; Moschetta, A.; Lee, Y.-K.; Peng, L.; Zhao, G.; Downes, M.; Yu, R. T.;
Shelton, J. M.; Richardson, J. A.; Repa, J. J.; Mangelsdorf, D. J.; Kliewer, S. A. Proc.
Natl. Acad. Sci. U.S.A. 2006, 103, 3920.
16. Jung, D.; Inagaki, T.; Gerard, R. D.; Dawson, P. A.; Kliewer, S. A.; Mangelsdorf, D.
J.; Moschetta, A. J. Lipid Res. 2007, 48, 2693.
17. Huang, W.; Ma, K.; Zhang, J.; Qatanani, M.; Cuvillier, J.; Liu, J.; Dong, B.; Huang,
X.; Moore, D. D. Science 2006, 312, 233.
18. Liu, Y.; Binz, J.; Numerick, M. J.; Dennis, S.; Luo, G.; Desai, B.; MacKenzie, K. I.;
Mansfield, T. A.; Kliewer, S. A.; Goodwin, B.; Jones, S. A. J. Clin. Invest. 2003, 112,
1678.
19. Fiorucci, S.; Clerici, C.; Antonelli, E.; Orlandi, S.; Goodwin, B.; Sadeghpour, B. M.;
Sabatino, G.; Russo, G.; Castellani, D.; Willson, T. M.; Pruzanski, M.; Pellicciari,
R.; Morelli, A. J. Pharmacol. Exp. Ther. 2005, 313, 604.
20. Stedman, C.; Liddle, C.; Coulter, S.; Sonoda, J.; Alvarez, J. G.; Evans, R. M.;
Downes, M. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11323.
36. Anderson, L. C.; Thomas, D. G. J. Am. Chem. Soc. 1943, 65, 234.
37. Lu, Y.-H.; Luo, X.-H.; Yang, C.-L. Ranliao Yu Ranse 2005, 42, 34.
38. For X-ray co-crystal preparation,
a FXR ligand binding domain protein
construct was purified by nickel-nitrilotriacetic acid affinity chromatography,
followed by thrombin cleavage of the histidine tag, then anion exchange
chromatography,
and
finally
gel
filtration
with
10 mM
tris(hydroxymethyl)aminomethane, pH 8.0, 120 mM sodium chloride,
0.1 mM ethylenediaminetetraacetic acid, 5 mM dithiothreitol, and 3% 1,2-
propanediol buffer. FXR ligands were added to 3 molar protein equivalents
(from 50 mM dimethyl sulfoxide stock) and incubated on ice for 1 h. A peptide
fragment (741–761SRC-1, K-E-S-K-D-H-Q-L-L-R-Y-L-L-D-K-D-E-K-D-L-R) derived
from steroid receptor coactivator-1 (SRC-1) was added to 1.5 mol protein
equivalents and incubated on ice for another hour. The protein complexes were
concentrated to 12 mg/ml or higher and crystallized by hanging drop vapor
diffusion around the conditions 0.1 M Bis(2-hydroxyethyl)-imino-
tris(hydroxymethyl)-methane, pH 6.5, 0.2 M lithium sulfate, and 20%
polyethylene glycol 4000. The crystals were frozen by stepwise exchange
into the same buffer, with 30% glycerol, followed by plunging into liquid
nitrogen.
39. Mi, L.-Z.; Devarakonda, S.; Harp, J. M.; Han, Q.; Pellicciari, R.; Willson, T. M.;
Khorasanizadeh, S.; Rastinejad, F. Mol. Cell 2003, 11, 1093.
21. Fiorucci, S.; Antonelli, E.; Rizzo, G.; Renga, B.; Mencarelli, A.; Riccardi, L.;
Orlandi, S.; Pellicciari, R.; Morelli, A. Gastroenterology 2004, 127, 1497.